Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | GAPDH | P04406 | 1/20 | 0.32 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.31 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.31 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.31 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29881527 | 0.95 | TYMP (0.34) | TYMPPRMT6ADORA2AADORA2BGAPDH | |
| SCHEMBL5558224 | 0.95 | TYMP (0.34) | TYMPPRMT6ADORA2AADORA2BGAPDH | |
| SCHEMBL1096766 | 0.95 | TYMP (0.34) | TYMPPRMT6ADORA2AADORA2BGAPDH | |
| SCHEMBL23827254 | 0.88 | TYMP (0.33) | TYMPPRMT6ADORA2AADORA2BGAPDH | |
| SCHEMBL30898734 | 0.88 | TYMP (0.33) | TYMPPRMT6ADORA2AADORA2BGAPDH | |
| SCHEMBL1667985 | 0.88 | TYMP (0.34) | TYMPPRMT6ADORA2AADORA2BGAPDH | |
| SCHEMBL1665982 | 0.88 | TYMP (0.34) | TYMPPRMT6ADORA2AADORA2BGAPDH | |
| SCHEMBL20394008 | 0.88 | TYMP (0.32) | TYMPPRMT6ADORA2AADORA2BGAPDH | |
| SCHEMBL23827276 | 0.88 | TYMP (0.33) | TYMPPRMT6ADORA2AADORA2BGAPDH | |
| SCHEMBL4620914 | 0.88 | CDK5 (0.34) | TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1152009-B2 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | DAIICHI SANKYO CO LTD (JP) | 2017-09-06 | — | — | EP | claimed |
| EP-1152009-B1 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | SANKYO CO (JP) | 2005-01-26 | — | — | EP | claimed |
| US-20230348522-A1 | METHOD FOR PRODUCING BICYCLIC PHOSPHORAMIDITE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-11-02 | — | — | US | disclosed |
| US-9885036-B2 | Double-stranded polynucleotide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-02-06 | — | — | US | disclosed |
| US-9657049-B2 | ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors | Matsuo, Masafumi (JP) | 2017-05-23 | — | — | US | disclosed |
| US-9657050-B2 | ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors | Masafumi, Matsuo (JP) | 2017-05-23 | — | — | US | disclosed |
| EP-2530153-B1 | ENA nucleic acid drugs modifying splicing in mRNA precursor | MATSUO MASAFUMI (JP) | 2016-03-16 | — | — | EP | disclosed |
| EP-2530155-B1 | ENA nucleic acid drugs modifying splicing in mRNA precursor | MATSUO MASAFUMI (JP) | 2016-03-16 | — | — | EP | disclosed |
| EP-2530154-B1 | ENA nucleic acid drugs modifying splicing in mRNA precursor | MATSUO MASAFUMI (JP) | 2016-03-16 | — | — | EP | disclosed |
| US-9243026-B2 | ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-26 | — | — | US | disclosed |
| US-20160002636-A1 | ENA NUCLEIC ACID PHARMACEUTICALS CAPABLE OF MODIFYING SPLICING OF mRNA PRECURSORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-07 | — | — | US | disclosed |
| EP-2374885-A2 | ENA nucleic acid drugs modifying splicing in mRNA precursor | Matsuo, Masafumi (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110152353-A1 | DOUBLE-STRANDED POLYNUCLEOTIDE | DAIICHI SANKYO COMPANY, LIMITED | 2011-06-23 | — | — | US | disclosed |
| US-7902160-B2 | ENA nucleic acid drugs modifying splicing in mRNA precursor | Matsuo, Masafumi (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20110046360-A1 | ENA NUCLEIC ACID DRUGS MODIFYING SPLICING IN mRNA PRECURSOR | Matsuo, Masafumi (JP) | 2011-02-24 | — | — | US | disclosed |
| EP-2135948-A2 | ENA nucleic acid drugs modifying splicing in mRNA precursor | Matsuo, Masafumi (JP) | 2009-12-23 | — | — | EP | disclosed |
| US-20070117773-A1 | Telomerase-inhibiting ENA oligonucleotide | SANKYO COMPANY, LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| EP-1783216-A1 | TELOMERASE-INHIBITORY ENA OLIGONUCLEOTIDE | Sankyo Company, Limited (JP) | 2007-05-09 | — | — | EP | disclosed |
| US-20070082861-A1 | Ena nucleic acid drugs modifying splicing in mrna precursor | MASAFUMI MATSUO (JP) | 2007-04-12 | — | — | US | disclosed |
| EP-1568769-A1 | ENA NUCLEIC ACID DRUGS MODIFYING SPLICING IN mRNA PRECURSOR | Matsuo, Masafumi (JP) | 2005-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152353-A1 | DOUBLE-STRANDED POLYNUCLEOTIDE | NSUN2, TRDMT1, POLRMT | TYMP 151/4885PRMT6 574/4885ADORA2A 1521/4885 |
| US-20070117773-A1 | Telomerase-inhibiting ENA oligonucleotide | TERT, ENO1, TERB1 | TYMP 59/4885PRMT6 2148/4885ADORA2A 912/4885 |
| US-20110046360-A1 | ENA NUCLEIC ACID DRUGS MODIFYING SPLICING IN mRNA PRECURSOR | SNRPA, RBM17, SNRPA1 | TYMP 526/4885PRMT6 1467/4885ADORA2A 577/4885 |
| US-20230348522-A1 | METHOD FOR PRODUCING BICYCLIC PHOSPHORAMIDITE | PFAS, ENPP1, NAAA | TYMP 113/4885PRMT6 2053/4885ADORA2A 2111/4885 |
| US-20070082861-A1 | Ena nucleic acid drugs modifying splicing in mrna precursor | SNRPA, RBM17, SNRPA1 | TYMP 526/4885PRMT6 1467/4885ADORA2A 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.